Bio-Rad and NuProbe enter into an exclusive licensing agreement for digital PCR applications
Nov. 10, 2022
Bio-Rad Laboratories, Inc. and NuProbe USA, announced the signing of a licensing and product development agreement.
Under the terms of the agreement, NuProbe USA will exclusively license its allele enrichment technologies to Bio-Rad for the development of multiplexed digital PCR assays. This technology will help to advance Bio-Rad’s menu of products in oncology, where highly sensitive and multiplexed mutation detection assays aid translational research, therapy selection, and disease monitoring.
